Physician profile
Ramin Altaha
NPI 1083649982
$12,791.01
in general payments reported to CMS, 2019-2025
56 companies · $326 in 2025
The $326 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,155 · 2020: $1,785 · 2021: $1,698 · 2022: $2,020 · 2023: $1,321 · 2024: $1,487 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Long Term Medical Supply Or Device Loan: $466 · Education: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.03 |
| Long Term Medical Supply Or Device Loan | $465.76 |
| Education | $385.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,984.44 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Novartis Pharmaceuticals Corporation | $1,225.50 | 2019-2025 | |
| Pfizer INC. | $1,210.79 | 2019-2025 | |
| Incyte Corporation | $1,052.40 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $1,025.38 | 2019-2024 | Imfinzi, Enhertu |
| Astellas Pharma US INC | $1,018.35 | 2019-2025 | Xtandi, Vyloy |
| Janssen Biotech, INC. | $864.48 | 2019-2025 | Erleada |
| Lilly USA, LLC | $607.22 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $552.47 | 2019-2022 | |
| Genzyme Corporation | $381.83 | 2019-2025 | |
| Genentech USA, INC. | $311.54 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.28 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $164.19 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $160.14 | 2022 | |
| Amgen INC. | $152.04 | 2019-2020 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramin Altaha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.